Primary ovarian carcinosarcoma: Confronting a lethal tumor
Authors:
Open Access
- 1 April 2026
- journal article
- Published by Wolters Kluwer Health in Journal of Integrative Medicine and Research
- Vol. 4 (2) , 163-166
Abstract
Ovarian carcinosarcoma (OCS) is a rare and aggressive malignant mixed Müllerian tumor, accounting for <2% of all ovarian malignancies. Characterized by biphasic histology with epithelial and mesenchymal components, OCS predominantly affects postmenopausal women and carries a poor prognosis. Early diagnosis is challenging due to a nonspecific clinical presentation, often requiring a combination of imaging. A 51-year-old postmenopausal woman presented with lower abdominal pain, postmenopausal spotting, and significant weight loss. Imaging revealed bilateral solid–cystic adnexal masses with metastases to the peritoneum, omentum, and stomach. The initial biopsy suggested high-grade serous carcinoma. Histopathology confirmed a diagnosis of OCS, revealing both carcinomatous and sarcomatous elements. OCS is an uncommon and highly aggressive neoplasm that requires detailed histopathological examination and immunohistochemistry for identifying its biphasic nature. Multimodal management combining surgery and chemotherapy remains the cornerstone of treatment. Awareness and early recognition are critical to improving clinical outcomes in affected patients.Keywords
This publication has 11 references indexed in Scilit:
- Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinomaBritish Journal of Cancer, 2022
- A rare and distinct bilateral ovarian tumor: CarcinosarcomaClinical Case Reports, 2021
- Communication between EMT and PD-L1 signaling: New insights into tumor immune evasionCancer Letters, 2020
- HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapyLaboratory Investigation, 2019
- Biphasic malignant tumours of the abdominal cavityInternational Journal of Clinical Oncology, 2017
- KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in miceInternational Journal of Cancer, 2017
- “Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities”Gynecologic Oncology, 2016
- Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcomeGynecologic Oncology, 2013
- The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?American Journal of Obstetrics and Gynecology, 2012
- Epithelial–Mesenchymal Transition in Ovarian CarcinomaFrontiers in Oncology, 2012